# DeepSeek V4.1 Flash / mol-r03

Original final answer, shared by both scoring rounds.

## Recommended next biological question

**Does the amino-terminal gasdermin D fragment directly execute membrane injury on protein-free lipid membranes, or does it require/activate a distinct cellular component that executes the injury?**

This is the highest-value next question because the supplied packet reports that inflammatory caspases cleave gasdermin D; that genetic loss and fragment-expression experiments link processing to pyroptotic death; and that the amino-terminal portion carries cytotoxic activity. The packet also states explicitly that these observations **do not reveal what physical action the fragment performs or whether another cellular component executes membrane injury**, and that **no subsequent purified-protein membrane experiments are supplied**. The unresolved gap is therefore not whether processing correlates with death, but whether the N-terminal fragment is itself a direct membrane-damaging executioner or an upstream activator/recruiter of a separate executioner.

The decisive first move is a preregistered, blinded minimal-reconstitution study: purified N-terminal fragment plus defined lipids, with no other cellular components. If the fragment alone injures pure membranes, it is a direct executor; then discriminate pore versus non-pore physical action. If it does not, the burden shifts to identifying the required cellular cofactor/executor.

---

## Evidence-to-inference-to-conclusion chain

### Reported in the packet

1. **Evidence:** Inflammatory caspases cleave gasdermin D.
2. **Evidence:** Genetic loss and fragment-expression experiments link this processing to pyroptotic cell death.
3. **Evidence:** The amino-terminal portion carries cytotoxic activity.
4. **Evidence:** The packet states that these observations do not, on their own, reveal what physical action the fragment performs or whether another cellular component executes membrane injury.
5. **Evidence:** No purified-protein membrane experiments are supplied.

### Inferences from the packet

- **Inference A:** Gasdermin D processing is causally linked to pyroptosis in cellular systems.
- **Inference B:** The N-terminal fragment is sufficient to produce cytotoxicity in the tested cellular contexts.
- **Inference C:** The physical mechanism of membrane injury and the possible requirement for a non-gasdermin executor remain unresolved.
- **Inference D:** Because no purified-protein membrane experiment is supplied, the field cannot currently distinguish direct membrane action from indirect cofactor-dependent action.

### Conclusion from the packet alone

The packet justifies the conclusion that gasdermin D cleavage and the N-terminal fragment are linked to pyroptotic death, but it does **not** justify the conclusion that the N-terminal fragment itself physically disrupts membranes, nor that it forms a pore, nor that it acts alone. The unresolved question is whether the fragment is a direct executor or an indirect activator of another membrane-injury component.

---

## Competing mechanisms and discriminating predictions

| Mechanism | Proposed molecular behavior | Minimal liposome prediction | Planar bilayer prediction | Cellular prediction | Key discriminating controls |
|---|---|---|---|---|---|
| **1. Direct pore-forming executor** | N-terminal fragment binds lipids, inserts, oligomerizes, forms a conductive pore | Dose- and time-dependent leakage; size-selective permeabilization; lipid-composition dependence | Discrete stepwise conductance increases; stable open states; ion selectivity; voltage sensitivity possible | N-terminal fragment should injure membranes when isolated; mutations blocking insertion/oligomerization should block death | Full-length GSDMD, C-terminal fragment, tag-only, heat-inactivated N, detergent positive control |
| **2. Direct non-pore membrane disruption** | N-terminal fragment binds and disorganizes lipids, causing thinning, curvature, lipid scrambling, or fragmentation | Continuous leakage; poor size selectivity; membrane fragmentation/tubulation; no stable discrete conductance | Continuous noisy conductance or rupture; no reproducible stepwise pore | Direct injury in minimal system, but not via defined pore; may be less size-selective | Lipid-mixing, membrane-morphology, and all-size leakage assays |
| **3. Indirect activator/recruiter** | N-terminal fragment binds a membrane or cytosolic cofactor, which then executes injury | No injury with pure lipids alone; injury restored by active cytosolic/membrane fraction | No direct conductance unless cofactor is present | Cellular injury requires the cofactor; depletion of cofactor blocks death downstream of GSDMD cleavage | Mock fractions, boiled fractions, protease-treated fractions, fractionation and reconstitution |

A fourth formal possibility is **mixed**: direct weak membrane binding by the N-terminal fragment plus a required cofactor for efficient injury. This predicts binding without permeabilization, or permeabilization only at high concentrations or specific lipid compositions. It is important because a negative minimal-system result would not by itself exclude membrane binding.

---

## Proposed research plan

### 0. Preregistration and definitions

**Proposed.** Before experiments, define:

- Primary question: Is purified N-terminal gasdermin D sufficient to injure protein-free lipid membranes?
- Primary endpoint for liposomes: normalized content leakage at a predefined time after protein addition.
- Primary endpoint for planar bilayers: frequency of discrete conductance steps or continuous conductance change.
- Secondary endpoints: binding, lipid mixing, membrane morphology, oligomerization, ion selectivity.
- Positive outcome threshold: reproducible, dose-dependent membrane injury in at least two independent protein preparations and two independent lipid compositions, with negative controls clean and positive controls working.
- Negative outcome threshold: no membrane injury at the highest soluble, QC-passed concentration, in at least two independent protein preparations and two lipid compositions, while positive controls work.
- Ambiguous outcome: binding without injury; injury only at high concentration; injury only in some lipid compositions; inconsistent across protein preparations; or direct injury in one membrane system but not another.

**Assumption:** The exact GSDMD constructs, cleavage sites, caspase identity, and purification methods are not supplied in the packet. They are prerequisites. Use the same constructs as the source cellular work if available, or clearly state substitute constructs as assumptions. Do not silently invent missing methods.

---

### 1. Prerequisites and reagent qualification

**Proposed.**

#### 1.1 Protein reagents

- Purified full-length gasdermin D.
- Purified N-terminal fragment.
- Purified C-terminal fragment.
- Cleavage-deficient or cleavage-resistant full-length mutant, if available.
- Tag-only or empty-vector mock purification.
- Heat-inactivated N-terminal fragment.
- Inflammatory caspase used for cleavage, if the N-terminal fragment is generated by in vitro cleavage.

Qualify each by:
- SDS-PAGE and densitometry.
- Mass spectrometry or intact mass to confirm identity and boundaries.
- Size-exclusion chromatography to assess monodispersity.
- Endotoxin measurement if protein is produced in bacteria.
- Protein concentration by A280 or quantitative amino acid analysis.
- Functional cleavage assay if generated by caspase cleavage.

**Critical control:** tag-cleaved versus tagged protein. Tags can alter membrane binding.

#### 1.2 Lipid reagents

Use defined synthetic lipids. Prepare at least two independent lipid compositions:
- A mammalian plasma-membrane-like composition.
- A composition varying cholesterol, charge, and lipid order.

Justify compositions as proposed; the packet does not specify the relevant pyroptotic membrane lipid composition. Record lipid purity, oxidation status, and lot numbers. Prepare liposomes fresh or freeze under validated conditions.

#### 1.3 Membrane systems

Use at least two orthogonal systems:
- Large unilamellar vesicles for content leakage.
- Giant unilamellar vesicles for morphology and single-vesicle permeabilization.
- Planar lipid bilayers for single-channel/conductance analysis.

If resources permit, add supported bilayers for binding and insertion.

---

### 2. Calibration and positive/negative controls

**Proposed.**

#### 2.1 Leakage calibration

- 0% leakage: buffer only.
- 100% leakage: detergent lysis of liposomes.
- Establish fluorescence linear range.
- Remove free dye rigorously; verify by gel filtration or dialysis.
- Use at least two encapsulated dyes or dextran sizes to test size selectivity.

#### 2.2 Planar bilayer calibration

- Minimum seal resistance and capacitance consistent with a stable bilayer.
- Positive control: a validated membrane-permeabilizing agent available in the laboratory. Identity should be chosen before study; it is not supplied by the packet.
- Negative control: buffer only.
- Test voltage protocol and reversal potential for ion selectivity.

#### 2.3 Protein controls

- Buffer only.
- Full-length gasdermin D.
- C-terminal fragment.
- Tag-only mock.
- Heat-inactivated N-terminal fragment.
- Caspase alone, if relevant.
- N-terminal fragment plus a known blocking condition, if available.

---

### 3. Experiment 1: Minimal reconstitution — does GSDMD-N directly injure pure membranes?

**Proposed.**

#### 3.1 Liposome content-leakage assay

- Prepare liposomes encapsulating a fluorescent dye or dextrans of different sizes.
- Add purified N-terminal fragment at a pre-registered dose series.
- Measure fluorescence over time.
- Normalize leakage:  
  `% leakage = (F_sample - F_baseline) / (F_detergent - F_baseline) × 100`.
- Run independent protein preparations and independent liposome preparations.

**Measurements:**
- Dose-response curve.
- Time course.
- Size selectivity using different dextrans.
- Lipid-composition dependence.

**Analysis:**
- Fit Hill equation for EC50 and Hill slope.
- Mixed-effects model with protein prep and liposome prep as random effects.
- Pre-specified exclusion: leaky vesicles at baseline, failed positive control.

#### 3.2 Giant unilamellar vesicle assay

- Encapsulate dye inside GUVs.
- Add N-terminal fragment.
- Image by fluorescence microscopy.
- Score permeabilization, membrane deformation, tubulation, fragmentation, and lysis.

**Independent unit:** individual GUV, but analyze with hierarchical model nested within independent GUV preparation.

**Blinding:** analyst blinded to protein identity and condition. Randomize field selection and acquisition order.

#### 3.3 Planar bilayer conductance

- Add N-terminal fragment to one side or both sides of a stable planar bilayer.
- Measure current at multiple voltages.
- Look for discrete stepwise conductance increases versus continuous leak.

**Measurements:**
- Conductance step size.
- Open probability.
- Reversal potential.
- Voltage dependence.
- Ion selectivity.

**Independent unit:** independent bilayer/aperture.

#### 3.4 Stop rule for Experiment 1

- If N-terminal fragment causes reproducible, dose-dependent leakage and conductance in pure membranes across two protein preps and two lipid compositions, while controls behave as expected: **proceed to mechanism discrimination**.
- If no injury at the highest soluble, QC-passed concentration in two protein preps and two lipid compositions, while positive controls work: **stop direct-executor hypothesis** and proceed to cofactor identification.
- If injury occurs only at concentrations far above a pre-registered biological range, or only in one lipid composition, treat as ambiguous and troubleshoot before concluding.

---

### 4. Experiment 2: Discriminate pore versus non-pore physical action

**Proposed.** This experiment is conditional on direct membrane injury being observed.

#### 4.1 Pore hypothesis predictions

- Discrete conductance steps in planar bilayers.
- Stable conductance states.
- Size-selective leakage: small dextrans leak, large dextrans do not.
- Oligomerization detectable by crosslinking, native PAGE, single-molecule photobleaching, or cryo-EM.
- Lipid-composition dependence consistent with insertion/oligomerization.

#### 4.2 Non-pore disruption predictions

- Continuous, noisy conductance or rupture.
- Poor size selectivity: large and small dextrans leak similarly.
- Membrane fragmentation, tubulation, or lipid mixing without discrete pores.
- No requirement for stable oligomerization.
- Leakage may correlate with membrane curvature or lipid order.

#### 4.3 Measurements

- Dextran leakage panel.
- Single-channel conductance.
- Lipid mixing and scrambling assays.
- Cryo-EM or negative-stain EM of protein-lipid mixtures.
- Binding affinity and insertion assays.
- Oligomerization state.

#### 4.4 Analysis

- Pre-specify primary mechanism call:
  - **Pore:** discrete steps plus size selectivity.
  - **Non-pore:** continuous leakage plus poor size selectivity.
  - **Ambiguous:** mixed features.
- Use nonparametric tests for step-size distributions.
- Use mixed-effects models for leakage across dextran sizes.

#### 4.5 Stop rules

- If discrete steps and size selectivity are reproducible: conclude direct pore-forming action under tested conditions.
- If continuous, nonselective leakage with membrane fragmentation: conclude direct non-pore disruption.
- If features conflict: conclude ambiguous; do not overclaim pore formation.

---

### 5. Experiment 3: Cofactor requirement and unbiased identification

**Proposed.** This is the essential branch if GSDMD-N fails to injure pure membranes.

#### 5.1 Cell-free reconstitution with fractions

- Prepare pure lipid membranes.
- Add purified N-terminal fragment.
- Add cytosolic and/or membrane fractions from relevant cells.
- Test whether injury is restored.

#### 5.2 Fractionation

- Fractionate active extracts by chromatography.
- Re-test fractions in the minimal system.
- Use protease treatment, boiling, and mock fractions as controls.
- Identify active components by mass spectrometry.

#### 5.3 Independent units and blinding

- Independent cell extract preparations.
- Blinded fraction collection and assay.
- Randomize fraction plate positions.

#### 5.4 Controls

- Mock fractions from non-expressing cells.
- Boiled active fractions.
- Protease-treated active fractions.
- N-terminal fragment alone.
- Fraction alone.

#### 5.5 Analysis

- Activity score per fraction.
- Enrichment across purification steps.
- Mass spectrometry identification with false-discovery control.

#### 5.6 Stop rules

- If a fraction reproducibly restores injury, proceed to candidate validation.
- If no fraction restores injury after validated fractionation, consider technical failure first: protein inactivity, fraction instability, missing membrane component, or inappropriate membrane composition.

---

### 6. Experiment 4: Orthogonal cellular validation

**Proposed.** Only after in vitro mechanism or cofactor is identified.

- If direct pore action: test whether mutations that block lipid binding, insertion, or oligomerization block pyroptotic death in cells.
- If direct non-pore action: test whether mutations that block membrane binding or lipid disordering block death.
- If cofactor required: deplete or knock out the candidate cofactor and test whether death is blocked downstream of gasdermin D cleavage.

**Independent unit:** independent edited cell clones or independent donor cells.

**Blinding:** genotype blinded during imaging and death scoring.

**Controls:** non-targeting guide, catalytically dead cofactor mutant, rescue with wild-type cofactor.

---

## Troubleshooting

**Proposed.**

1. **Protein aggregation or inactivity**
   - Re-purify by size-exclusion chromatography.
   - Test fresh versus freeze-thawed protein.
   - Optimize salt, pH, reducing agent, and arginine.
   - Verify by dynamic light scattering and activity assay.

2. **Tag interference**
   - Compare tagged versus tag-cleaved protein.
   - Include tag-only mock.

3. **Lipid artifacts**
   - Control lipid oxidation.
   - Test multiple lipid compositions and cholesterol levels.
   - Use fresh liposomes and validated extrusion.

4. **Dye artifacts**
   - Remove free dye completely.
   - Use dual-dye or dextran size panels.
   - Correct for inner-filter effects.

5. **Planar bilayer instability**
   - Pre-register seal resistance and capacitance criteria.
   - Use solvent-free or low-solvent bilayers if possible.
   - Exclude noisy or unstable bilayers before unblinding.

6. **Cofactor fractionation failure**
   - Use protease inhibitors and cold handling.
   - Maintain membrane and cytosolic fractions separately.
   - Test fractions on pure lipids with and without N-terminal fragment.
   - Consider that the required cofactor may be a specific lipid, not a protein.

---

## Conditional outcomes and strongest justified conclusions

### Positive outcome: direct membrane injury by GSDMD-N

**Observed pattern:** Purified N-terminal fragment causes dose-dependent, reproducible membrane injury in pure lipid systems. Discrete conductance steps and size-selective leakage indicate a pore; continuous leakage and membrane fragmentation indicate non-pore disruption.

**Strongest justified conclusion:** Under the tested minimal conditions, the N-terminal gasdermin D fragment is a direct executor of membrane injury. If pore-like, it directly forms a conductive membrane lesion. If non-pore-like, it directly disrupts membrane integrity without requiring another cellular component for the injury step.

**Important limit:** Direct in vitro action does not exclude cellular modulation by lipids, cofactors, or membrane trafficking.

### Negative outcome: no direct membrane injury

**Observed pattern:** Purified N-terminal fragment fails to injure pure membranes at the highest soluble, QC-passed concentration, while positive controls work and protein QC passes.

**Strongest justified conclusion:** Under the tested conditions, the N-terminal fragment alone is insufficient to execute membrane injury. Another cellular component is required for membrane injury downstream of gasdermin D cleavage. The fragment may still bind membranes or act as an activator/scaffold.

**Important limit:** Negative results are condition-dependent. Different lipids, pH, ionic strength, or protein modifications could change the result. The conclusion is “not sufficient under tested conditions,” not “never sufficient.”

### Ambiguous outcome

**Observed pattern:** Binding without permeabilization; permeabilization only at high concentration; injury only in one lipid composition; direct injury in liposomes but not planar bilayers; or inconsistent protein preparations.

**Strongest justified conclusion:** The evidence cannot yet distinguish direct execution from cofactor-dependent execution. The next step is orthogonal confirmation and cofactor identification. Do not claim pore formation or direct execution from ambiguous data.

---

## Summary recommendation

The most valuable next question is: **Is purified gasdermin D N-terminal fragment sufficient to injure pure lipid membranes, and if so, by what physical mechanism?** The packet currently reports a cellular link between gasdermin D cleavage, the N-terminal fragment, and pyroptotic death, but explicitly lacks the purified-protein membrane experiments needed to determine physical action or whether another cellular component executes injury. The proposed plan starts with minimal reconstitution, uses orthogonal membrane systems, preregisters primary endpoints, blinds analysis, includes full-length/C-terminal/tag/heat-inactivated controls, and branches to cofactor identification if direct action is not observed. This design directly resolves the stated gap and avoids overclaiming mechanisms that the supplied evidence does not establish.
